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Abstract 
The acceptance by a large number of state governments of medical marijuana dispensaries and the regulatory framework to support 
their licensing has put to one side the issue of monitoring and reporting outcomes. This is a major oversight. It is an untenable situation 
given the limited evidence base for the clinical benefits and risks associated with dispensed botanical marijuana. The purpose of this 
commentary is to propose that, as a condition of licensing, marijuana dispensaries should be required to establish a registry to support 
ongoing monitoring of patient response associated with botanical cannabis formulations. Patients should be monitored over the course 
of their treatment to assess, in the case of severe non-cancer pain as an example, pain intensity and functional status by pain location. 
The dispensary, in meeting required audit standards, should be in a position to report on patient response over baseline to the provider 
who has recommended botanical cannabis. As well, registries should be in a position to report to state licensing agencies response to 
therapy by target patient groups. Establishing site-specific registries should go some way to meeting the present evidence deficit for 
botanical marijuana, reducing barriers to its acceptance by providers, patients and health agencies. 
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Introduction 
One of the more puzzling features of the embrace by many 
state governments in the US of medical marijuana programs is 
the apparent lack of interest in establishing dispensary 
standards for monitoring the use and impact of botanical 
marijuana formulations on therapy outcomes. Rather, the focus 
is on establishing the regulatory basis for licensing and 
production. Outcomes of therapy associated with the choice of 
marijuana formulations either alone or in combination with 
prescription medications are essentially ignored. The net result 
is that while there is mandatory reporting to state agencies of 
some limited characteristics of dispensary cannabis users, we 
have little idea on whether or not the ability to access 
marijuana through dispensaries has a clinically significant 
impact on the course of a disease or symptoms reported. We 
have no idea of the distribution of outcomes associated with 
botanical marijuana within target patient groups together with 
the incidence of adverse events and the direct medical and 
social costs of treatment.  
 
Botanical marijuana is still a schedule 1 controlled substance 
under federal law, regulated by the Drug Enforcement Agency 
(DEA). It is not recognized by the FDA or approved for any 
therapeutic indication. It cannot be prescribed, only 
recommended by registered clinicians or other medical 
professionals as part of a patient certification process. This is in 
contrast to the FDA approved prescription cannabinoids: 
Marinol/Syndros (dronabinol), Cesamet (nabilone) and 
Epidiolex (cannabidiol) that are dispensed through pharmacies. 
Although the focus of this commentary is on the management  
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of botanical cannabis through state licensed dispensaries, the 
criticisms regarding monitoring and response to therapy apply 
equally to prescription cannabinoids. The important difference, 
however, is that with the prescription cannabinoids there is a 
body of randomized clinical trial (RCT) data that provide a 
baseline for the evaluation and replication of claims in target 
patient populations (e.g., Epidiolex in Lennox-Gastaut 
syndrome and Dravet syndrome). This is not the case for 
botanical cannabis. 
 
It should, perhaps, not be surprising that little attention is given 
to establishing standards and reporting platforms for the 
monitoring of the therapeutic impact of botanical marijuana in 
specific disease states and conditions for patients.  After all, 
these standards have yet to be developed outside of botanical 
medical marijuana 1 2. This is seen in the absence of data for the 
medium and long-term effectiveness of pain medications. 
Although opioids are the mainstay of therapy, evidence for 
their impact outside of short-term randomized clinical trials is 
lacking. The latest CDC Guidelines for Prescribing Opioids for 
Chronic Pain point out that evidence on long-term opioid 
therapy for chronic pain outside of end-of-life care remains 
limited, with insufficient evidence to determine long-term 
benefits versus alternative options or the absence of opioids 
altogether 3.  
 
Given the fact that well over 85% of patients for medical 
marijuana report chronic pain, the CDC criticism of opioids 
applies equally well to both botanical and prescription 
marijuana. Absent the RCT data for prescription marijuana and 
data capture through administrative claims, the situation is that 
to all intents and purposes botanical marijuana formulations 
are supplied through dispensaries in what is an evidence 
vacuum. This does not mean that there is not substantive 
ongoing clinical research into marijuana formulations involving 
several federal agencies including not only the FDA but the Drug 
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Enforcement Administration (DEA) and the National Institute 
on Drug Abuse (NIDA). Even so, in the case of dispensaries with 
the range of formulations and delivery modes available, we 
don’t have the luxury of waiting on the results of formal RCTs 
together with nationally sponsored pragmatic trials and 
observational studies to support possible FDA approvals (e.g., 
Sativex [nabiximols] in spasticity and nerve pain) or a more 
comprehensive evidence base to support dispensing decisions.  
 
The purpose of this commentary is to consider whether 
licensing and the renewal of licenses by state governments 
should be dependent upon those dispensaries meeting 
standards for reporting cannabis formulations supplied 
together with the monitoring and reporting of patient 
outcomes. Not only does this address the essentially 
personalized nature of botanical cannabis dispensing and 
administration given to range of options open, but it provides a 
needed contribution to a robust evidence base to support 
patient certification and dispensing decisions. 
 
It is not, however, only the standard of reporting to state 
dispensary licensing agencies that is at issue. Dispensaries 
should also be required to act as intermediaries between 
providers and patients in reporting on cannabis interventions. 
Well managed dispensaries could provide an ideal reference 
point for developing provider-mediated marijuana medication 
management and reporting systems. Providers should receive 
regular reports on their patient’s response to therapy, 
recognizing that in the area of severe pain, which is all too often 
a chronic condition, access to cannabis is only one element in 
an overall pain management strategy.  
 
The Evidence Base for Medical Marijuana 
Randomized clinical trial (RCT) data for outcomes in marijuana 
is overall of medium quality in its support for the development 
of prescription marijuana formulations. Whiting et al, in one of 
the more comprehensive systematic review of the benefits and 
adverse events associated with cannabinoids in a range of 
conditions and symptoms concluded that the evidence, at best, 
was of moderate quality and surprisingly limited 4. Their 
conclusion, for example, for a moderate quality evidence for 
cannabinoids in the treatment of severe pain and spasticity is 
based on 31 short-term (2- 14/15 week follow-up) randomized 
placebo controlled clinical trials (4,595 patients). Thirty of the 
trials were for a single product, nabiximols (Sativex) oromucosal 
spray which is not approved in the US. 
 
Deshpande et al report on six RCT studies for various 
formulations of medical marijuana in HIV peripheral 
neuropathy (2 studies), multiple sclerosis (one study), post-
traumatic neuropathy (one study) and neuropathic pain (2 
studies) 5. The studies varied in their protocols, with study 
periods from 17 days to 8 weeks, as well as in the cannabis 
strength and formulations, the delivery method (smoking, pipe 
and vaporization) and the primary therapy outcomes. 
Limitations in the number of high quality randomized trials have 
been reported by others. Hill reports on 28 RCTs in chronic pain 
(6 trials), neuropathic pain (6 trials) and 12 RCTs in multiple 
sclerosis, concluding that while several trials had positive 
results, there is clearly a case for additional trials as there are 
only a few indications for medical marijuana supported by high 
quality evidence. A further review of medical marijuana in 
chronic pain by Jensen et al points to the absence of ‘gold 
standard’ studies to enhance an otherwise limited evidence 
base 6. A similar conclusion holds in a recent review of medical 
cannabis for neuropathic pain 7. Although a number RCTs have 
demonstrated efficacy, the authors point out that they are 
limited by small sample sizes and short study duration. More 
studies are needed not only to determine the long run effects 
of cannabis, but to support claims for optimal dosing, 
cannabinoid ratios and alternative administration routes. 
 
Evidence for botanical marijuana formulations is limited to 
essentially ad hoc observational data. Most recently, for 
example, Stith et al report on a naturalistic observational 
research study involving responses to the Releaf AppTM  for the 
effectiveness and side effects of medical cannabis use 8. Users 
of the app (2,830) completed 13,683 individual sessions with 
self-administering cannabis, reporting their symptom rating on 
an 11-point visual analog scale together with side effects. The 
most frequently reported symptoms were pain, anxiety and 
depression. Overall, for the 27 symptom categories symptom 
severity level decreased as did the adjusted symptom relief 
measure (symptom relief plus negative side effects) for all but 
four symptom categories (convulsions, tremors, dizziness, 
excessive appetite). On average, most cannabis users 
experienced symptom relief. Unfortunately, the study suffers 
from a number of significant limitations: lack of a control group, 
limited evidence on patient characteristics and prior 
medication history, limited evidence on cannabis formulation 
and delivery method, lack of a structured framework for 
tracking treatment visits and limited outcomes measures.  
 
Observational studies are also limited by sample size. A smaller 
scale retrospective 3-month mirror-image study of 29 patients 
with chronic pain by Belliner et al utilizing both the EQ-5D 
quality of life instrument and the Pain Quality Assessment Scale 
(PQAS) found that medical cannabis both improved quality of 
life and reduced pain as well as reducing opioid use with cost 
savings  9. Set against these results, a further small scale recent 
study retrospective study of marijuana use in patients involved 
in motor vehicle accidents examined the association between 
marijuana use, opioid consumption and pain scores 10.  While 
only preliminary, the authors concluded that marijuana use, 
especially chronic use, may affect pain response to injury by 
requiring greater use of opioids. These conclusions are of 
interest given another recent retrospective chart review of 
cannabis use and opioid-related aberrant behaviors in the 
treatment of severe pain 11. The authors found a significant 
association with opioid use and recommended closer 
monitoring of those patients, particularly those with a history 
of substance abuse. 
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Overall, even with RCTs that meet minimum evidence 
standards there is still a dearth of RCT as well as observational 
studies to guide treatment regimens in botanical marijuana. 
This is seen in the case of older populations which are typically 
excluded from RCTs but who are a target for botanical cannabis 
therapy. Mahvan et al, in a recent review of marijuana use in 
the elderly, point to the lack of research and funding and the 
consequent scarcity of a reputable literature 12.  
 
It should also be noted that, a substantial number of patients 
may present with multiple conditions (e.g., severe pain and 
nausea) as well as comorbid conditions. This possibility places a 
premium on profiling patients, evaluating potential drug-drug 
interactions as well as monitoring response to therapy for 
multiple conditions and comorbidities. These would include 
depression, anxiety, and fatigue and sleep experience.  
 
Concerns raised as to the quality of evidence to support 
interventions in non-cancer severe pain apply equally to the 
range of other indications that have been proposed for 
dispensary cannabis: notably severe nausea, muscle spasms 
and seizures. Although severe non-cancer pain dominates 
medical conditions reported by dispensaries for active medical 
marijuana cardholders, the range of potential conditions is 
essentially open-ended with either the physician deciding the 
specific indications they will prescribe cannabis for or the 
regulator dictating only specific indications (from, typically, a 
growing list) 13. The number of potential combinations of 
formulation and applications for protocol design points to the 
limitations of only relying on ‘gold standard’ clinical trials to 
drive therapy choice. Without putting to one side the options 
for developing marijuana-based compounds for FDA approval 
and marketing, the diversity in botanical marijuana 
formulations points to the need for a broader reference frame 
for monitoring and reporting the application and outcomes of 
botanical cannabis dispensing.  
 
Dispensaries as a Pragmatic Evidence Base 
The importance of establishing a monitoring and reporting 
system for patients utilizing dispensary services should be seen, 
not only against the fact that evidence for the benefits of 
botanical marijuana is limited but that ‘(the) biological 
complexity and variability, quality control issues, previous 
dearth of appropriately powered randomized controlled trials, 
and lack of pertinent treatment have conspired to leave 
physicians in the dark as to how to advise patients pursuing 
such treatment …this ignorance of cannabis pharmacology and 
therapeutics has become untenable 14.  
 
At the same time, from the perspective of severe pain (and the 
same case can be made in other therapy areas) we know very 
little regarding the clinical profile of patients dispensed 
botanical marijuana, the type, intensity and location of pain 
reported prior to treatment, the prevalence of neuropathic 
pain and mixed nociceptive and neuropathic conditions. To this 
we would add the potential for drug-drug interactions, prior 
response to therapy and risk for cannabis abuse, possibly in 
association with opioids. Unless a baseline standard for severe 
pain assessment and monitoring is established then it is 
impossible to judge whether the introduction of dispensary 
mediated botanical marijuana is not only clinically meaningful 
with an acceptable adverse event profile but, in more general 
terms, contributes to a beneficial impact on parameters such as 
quality of life over the timeframe of therapy. 
 
To establish a broader reference frame, a first priority should 
be for the monitoring of patients to create a real time database 
for dispensed botanical marijuana. To be clear: this is not a call 
for a national medical marijuana registry. It is a call for a point 
of care cannabis management registry and reporting system. In 
respect of severe non-cancer pain, for example, the question is 
whether or not the introduction of a specific medical marijuana 
formulation has, within a reasonable timeframe, a clinically 
meaningful impact on pain intensity and functional status? In 
the case of severe pain reporting pain intensity and functional 
status by pain location (and by neuropathic pain status) on a 
regular basis will provide feedback to determine effectiveness. 
This argument for monitoring the impact of adding cannabis to 
a treatment regimen or substituting cannabis for an opioid 
formulation is nothing more than a standard for evidence. The 
same argument could be applied to severe pain management 
in the absence of cannabis by specialist pain centers. The point 
to make is that introducing non-prescription marijuana to the 
treatment of non-cancer severe pain, after presumably initial 
and consequent non-cannabis therapy choices have failed, 
introduces a further element of uncertainty in the treatment of 
pain. This puts the emphasis on tracking and evaluating 
response to therapy both for the individual patient and for the 
various target patient groups (defined by condition/symptoms 
and recommended botanical formulation).  
 
Meeting standards for evaluation and replication of botanical 
marijuana claims also requires feedback in real time to the 
dispensing pharmacist and the provider who may have initially 
recommended and approved cannabis certification. This 
implies that the decision to recommended botanical marijuana 
by the provider is seen as part of a therapy or care management 
plan and not a one-off, cursory or shop-front assessment by a 
physician or technician employed by a dispensary to rubber-
stamp card authorizations, thus enabling legal access to 
cannabis.  
 
Dispensary: Staffing, Reporting and Licensing 
Given the paucity of evidence linking formulations to clinical 
presentations, it is important to ensure that the dispensary is 
appropriately staffed. This has been recognized by a number of 
states. Staff should meet minimum professional standards. 
These standards would apply, first, to the initial patient 
assessment by, for example an in-house physician or clinical 
pharmacist and, second, to the retail staff in their advice on 
delivery options given the initial patient assessment. 
Minnesota, New York and Connecticut, for example, require a 
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licensed pharmacist to be present during operating hours while 
Pennsylvania requires a licensed physician at the dispensary 
primary location. 
 
 In the absence of standards or licensing requirements for retail 
staff private operators have entered the market place. The 
quality and relevance of these programs to assessing 
recommended cannabis and monitoring patient use is 
unknown. A recent survey by Haug et al on the training and 
practices of cannabis dispensary staff (n = 55) found that while 
55% of dispensary staff reported some formal training only 20% 
reported medical/scientific training 15. While the majority (94%) 
reported providing specific cannabis advice to patients with 
many making recommendations consistent with available 
evidence, recommendations were also made for formulations 
that were either not supported by evidence or inconsistent with 
the patient’s condition. 
 
Standards should also apply to dispensary management. If the 
dispensary is to report, not just on individual patients but on 
the overall response to botanical formulations by target patient 
groups, then management reporting systems need to be staffed 
(or contracted out) to support the dispensary registry and 
ensure that a robust evidence base is created. Given the lack of 
high quality evidence to support claims for botanical marijuana 
puts the onus on the dispensary to demonstrate that 
appropriate account is being taken of the impact, the risks and 
benefits, of dispensed medical marijuana. 
 
In the case of severe pain, which as noted is the dominant 
symptom presented to dispensaries, the dispensary should be 
able to demonstrate that it is monitoring in real time against 
agreed and validated patient reported outcomes in pain 
intensity and functional status. The dispensary should be able 
to demonstrate that the appropriate titration protocols are 
being followed and that therapy adjustments reflect patient 
reporting of outcomes. At the same time, the dispensary should 
be able to demonstrate that it has procedures in place to report 
therapy outcomes to the patient’s provider and that there is 
sufficient evidence provided in real time to support decisions 
for continuing patient certification for medical marijuana use.  
 
Dispensary licensing, as a minimum should require an audit trail 
initiated at first dispensary visit to capture therapeutic 
response and adverse events. There needs to be a standardized 
patient record regarding the choice of initial cannabis 
formulation, dosing, titration recommendations and delivery 
system, and the reasons for supporting this choice. The workup 
to this choice should also include a documented medication 
review covering potential drug-drug interactions including 
pharmacogenomics considerations in choice of formulation and 
administration. The record should also capture any restrictions 
on the use of cannabis determined by the provider or the 
registration authorities together with a copy of any report to 
the provider regarding the initial patient workup and 
justification of choice of therapy.   
Following a baseline assessment of clinical status at cannabis 
initiation there should be regular assessments, either at 
dispensary visits or online, of response to therapy in key clinical 
parameters, adherence to therapy, potential changes in other 
medications and non-authorized cannabis utilization. This last 
issue becoming of interest where recreational marihuana use is 
legislated alongside medical marijuana with the potential for 
patients switching to recreational marijuana outlets to self-
medicate or new patients simply avoiding registration 
altogether.  
 
Conclusions 
The importance of monitoring therapy response and, for target 
patient groups, estimating the independent contribution of 
specific cannabis formulations to clinical outcomes are 
necessary steps in developing a needed evidence base for 
botanical marijuana. Such evidence would not only provide a 
justification for legislating approval for dispensaries but would 
also support physicians in their advice to patients that specific 
cannabis formulations, appropriately managed, may help to 
play a more central role in their duty of care. 
 
A marijuana dispensary is no different from any other specialist 
referral that a provider may recommend to a patient in the 
process of care. The evidence requirements and monitoring of 
patients by specialist referral providers are those that should 
apply to a dispensary. A key question registration authorities 
should ask, therefore, is what monitoring and reporting 
systems should be in place that allow the dispensary to assess 
the impact of a prescribed cannabis formulation on the process 
and outcomes of care? Could a failure to meet such standards 
be an element for refusing an initial dispensary license or 
refusing to review a license? Should we recognize that 
dispensaries have a duty of care; a duty that is no different from 
that asked of other health care providers? In the absence of 
such requirements by legislative authorities the result could be 
a ‘two-tier’ dispensary market with ‘duty of care’ dispensaries 
promoting a comprehensive initial assessment of patients by 
qualified clinical staff, monitoring patients over the course of 
their treatment and reporting response to therapy to the 
patient’s provider. Against this would be ‘shop front’ 
dispensaries that meet legislative requirements but lack not 
only clinical staff to support initial therapy decisions but also 
the infrastructure to monitor and report response to therapy.  
 
Failure to establish standards for the assessment by dispensary 
staff of therapy options together with standards for monitoring 
and reporting is unacceptable. If we are concerned to establish 
a robust evidence base to support claims for cannabis in 
therapy, then dispensaries should, ideally, be required to meet 
minimum standards for reporting response to therapy. If not, 
there Is the risk that  will be a reluctance or outright refusal by 
providers to consider cannabis as an acceptable therapy option 
in pain management or other conditions such as severe nausea 
and persistent muscle spasms.  
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